{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T04:07:01Z","timestamp":1746677221793,"version":"3.40.5"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>This study aimed to assess the diagnostic accuracy of a novel semiautomated method to calculate relative myocardial wall uptake (RCU) of <jats:sup>99m<\/jats:sup>Technetium-pyrophosphate SPECT\/CT in suspected cardiac transthyretin amyloidosis (ATTR).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Prospective analysis of 108 participants with suspected ATTR. Using novel software, we quantified radiopharmaceutical uptake in the wall of each chamber of the heart at 3\u2005h, calculating RCU for combined ventricular (RCU-V) and whole-heart (RCU-W) measures as a ratio over physiological blood-pool activity. Optimal RCU cut-off ratios were determined using a documented clinical diagnosis of ATTR amyloidosis as the reference standard.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The RCU-V method with a cut-off ratio of 1.2 achieved a sensitivity of 100% [95% confidence interval (CI): 90\u2013100%], specificity of 99% (95% CI: 95\u2013100%), and accuracy of 99% (95% CI: 96\u2013100%). The RCU-W method required a higher cut-off ratio of 1.4 to achieve a comparable specificity of 99%.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>This novel SPECT\/CT quantification software using the RCU-V method significantly improves diagnostic accuracy for cardiac ATTR and represents an advance compared to existing planar nuclear imaging assessment techniques.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mnm.0000000000001972","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T08:06:20Z","timestamp":1741766780000},"page":"533-538","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["99mTechnetium-pyrophosphate SPECT\/CT with novel semiautomated quantification has excellent diagnostic accuracy for detecting cardiac transthyretin amyloidosis"],"prefix":"10.1097","volume":"46","author":[{"given":"Saxby","family":"Brown","sequence":"first","affiliation":[{"name":"Nuclear Medicine and Ultrasound"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona","family":"Kwok","sequence":"additional","affiliation":[{"name":"Haematology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Evans","sequence":"additional","affiliation":[{"name":"Nuclear Medicine and Ultrasound"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Geenty","sequence":"additional","affiliation":[{"name":"Cardiology, Westmead Hospital, Westmead"},{"name":"Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liza","family":"Thomas","sequence":"additional","affiliation":[{"name":"Cardiology, Westmead Hospital, Westmead"},{"name":"Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Larcos","sequence":"additional","affiliation":[{"name":"Nuclear Medicine and Ultrasound"},{"name":"Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Farlow","sequence":"additional","affiliation":[{"name":"Nuclear Medicine and Ultrasound"},{"name":"Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"key":"R1-20250507","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12875-020-01252-4","article-title":"Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner.","volume":"21","author":"Gertz","year":"2020","journal-title":"BMC Fam Pract"},{"key":"R2-20250507","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association.","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"key":"R3-20250507","doi-asserted-by":"crossref","first-page":"102867","DOI":"10.1016\/j.cpcardiol.2024.102867","article-title":"Assessment of right ventricular myocardial stiffness by cardiac elastography in patients with transthyretin amyloidosis.","volume":"50","author":"Neto","year":"2024","journal-title":"Curr Probl Cardiol"},{"key":"R4-20250507","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J"},{"key":"R5-20250507","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1136\/heartjnl-2021-320131","article-title":"Prevalence, incidence and survival of heart failure: a systematic review.","volume":"108","author":"Emmons-Bell","year":"2022","journal-title":"Heart"},{"key":"R6-20250507","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis.","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"R7-20250507","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","article-title":"Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-DPD scintigraphy.","volume":"46","author":"Perugini","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R8-20250507","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s12350-016-0610-4","article-title":"Standardization of 99mTechnetium-pyrophosphate imaging methodology to diagnose TTR cardiac amyloidosis.","volume":"25","author":"Bokhari","year":"2018","journal-title":"J Nucl Cardiol"},{"key":"R9-20250507","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1007\/s12350-019-01760-6","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis.","volume":"26","author":"Dorbala","year":"2019","journal-title":"J Nucl Cardiol"},{"key":"R10-20250507","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1007\/s12350-021-02563-4","article-title":"Diagnostic and prognostic value of Technetium-pyrophosphate uptake quantitation for transthyretin cardiac amyloidosis.","volume":"28","author":"Miller","year":"2021","journal-title":"J Nucl Cardiol"},{"key":"R11-20250507","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s12350-022-03133-y","article-title":"99mTc-PYP SPECT and SPECT\/CT quantitation for diagnosing cardiac transthyretin amyloidosis.","volume":"30","author":"Nichols","year":"2023","journal-title":"J Nucl Cardiol"},{"key":"R12-20250507","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy.","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"R13-20250507","first-page":"69","article-title":"Myocardial damage of the entire ventricular region in a patient with acute myocardial infarction.","volume":"8","author":"Kawamata","year":"2020","journal-title":"Asia Ocean J Nucl Med Biol"},{"key":"R14-20250507","doi-asserted-by":"crossref","first-page":"83","DOI":"10.6004\/jnccn.2022.7077","article-title":"Immunoglobulin light chain amyloidosis: diagnosis and risk assessment.","volume":"21","author":"Zanwar","year":"2023","journal-title":"J Natl Compr Canc Netw"}],"container-title":["Nuclear Medicine Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MNM.0000000000001972","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T09:00:12Z","timestamp":1746608412000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MNM.0000000000001972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,12]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/mnm.0000000000001972","relation":{},"ISSN":["0143-3636","1473-5628"],"issn-type":[{"type":"print","value":"0143-3636"},{"type":"electronic","value":"1473-5628"}],"subject":[],"published":{"date-parts":[[2025,3,12]]}}}